- Home
- RNAZ
as 12-18-2024 12:42pm EST
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 4.9M | IPO Year: | 2021 |
| Target Price: | $99.00 | AVG Volume (30 days): | 30.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -71.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.31 - $264.00 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 233.33% |
Latest TransCode Therapeutics Inc. News
RNAZ Breaking Stock News: Dive into RNAZ Ticker-Specific Updates for Smart Investing
PR Newswire
5 hours ago
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
GlobeNewswire
19 days ago
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
TipRanks
20 days ago
Transcode Therapeutics issues 21.2M shares at 37.7c in private placement
MT Newswires
21 days ago
TransCode Therapeutics to Sell Securities Worth $8 Million in Private Placement
GlobeNewswire
21 days ago
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
TipRanks
22 days ago
Transcode Therapeutics announces 1-for-33 reverse stock split
GlobeNewswire
23 days ago
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
GlobeNewswire
a month ago
TransCode Therapeutics Open Letter to Shareholders
Compare RNAZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNAZ TransCode Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.